通过生活方式的改变调节microRNAs在阿尔茨海默氏症的疾病
Paola Pinto-Hernandez1,2, Juan Castilla-Silgado1,2, Almudena Coto-Vilcapoma1,2
1Department of Functional Biology, Physiology, University of Oviedo, 33006 Asturias, Spain.
Nutrients
|September 9, 2023
概括
饮食和体力活动 (PA) 等生活方式的改变会影响与阿尔茨海默病 (AD) 相关的微RNA (miRNA) 表达. 需要进一步的研究来探索这些miRNA变化作为潜在的生物标志物和AD的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 预防医学 预防医学
背景情况:
- 包括饮食和体力活动 (PA) 在内的生活方式因素被认为在预防和延迟阿尔茨海默病 (AD) 中发挥着重要作用.
- 微RNAs (miRNAs) 越来越多地被认为是各种疾病的潜在生物标志物,包括AD.
研究的目的:
- 在阿尔茨海默病的背景下,审查和分析现有的关于生活方式因素如何调节microRNA表达的文献.
- 确定当前关于AD生活方式-miRNA相互作用的研究中的差距和局限性.
主要方法:
- 文献综述侧重于研究检查生活方式因素 (饮食,PA) 和AD中miRNA表达之间的关系.
- 对人类 (循环miRNAs) 和动物 (脑组织miRNAs) 研究的分析.
- 在分析中预测已识别的miRNAs的功能角色.
主要成果:
- 特定的循环miRNAs (let-7g-5p,miR-107,miR-144-3p) 与轻度认知障碍患者的饮食质量相关.
- 这些miRNA与AD相关的途径,如粉样β积累和炎症有关.
- 身体活动对AD患者和小鼠的循环miRNAs (miR-129-5p,miR-192-5p) 和大脑miRNAs (miR-132,miR-15b-5p,miR-148b-3p,miR-130a-5p) 进行修改,影响神经元活动和炎症.
结论:
- 生活方式干预显示出调节与AD相关的miRNA表达的潜力.
- 识别的miRNAs代表了未来生物标志物发现和AD治疗策略的有希望的途径.
- 人类干预研究和详细的PA协议存在重大差距,需要进一步调查.
更多相关视频
相关概念视频
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517


